Wegovy Tablets vs Wegovy Injection: Which Is Right for You?

Wegovy Tablets vs Wegovy Injection: Which Is Right for You?

The journey toward sustainable weight management has seen significant advancements, and one of the most discussed is Wegovy (semaglutide). Traditionally available as a once-weekly injection, Wegovy has also been approved in the US as a once-daily tablet since December 22, 2025. This raises a new question for many: Which version is the better fit?

This guide offers a practical comparison between the Wegovy injection and Wegovy tablets (oral semaglutide). Approval and availability of the tablets outside the US vary by country, so check with your prescriber. The goal is not to recommend one over the other, but to provide clear, evidence-aware information so you can have a more informed conversation with your doctor. Consult your healthcare provider before starting any medication.

Understanding Semaglutide: The Active Ingredient

Before comparing the delivery methods, it’s helpful to understand the active ingredient they share: semaglutide.

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. In simple terms, it works by mimicking a natural hormone in your gut. This hormone sends signals to your brain that help regulate appetite, making you feel fuller and more satisfied after eating. It also slows down the rate at which your stomach empties, which can prolong the feeling of fullness.

Whether taken as an injection or a tablet, the fundamental goal of the semaglutide inside is the same: to work with your body’s own systems to help manage weight.

Wegovy Injection: The Established Option

The once-weekly Wegovy injection has been the standard form of this medication for weight management. It has been extensively studied and used by many people on their weight health journeys.

How It's Used

The Wegovy injection is administered once a week, on the same day each week, at any time of day. It’s a subcutaneous injection, which means it goes into the fatty tissue just under the skin. Common injection sites include the abdomen, thigh, or upper arm.

In the US, the medication comes in a pre-filled, single-use pen with a very fine needle (pen types differ in some other countries), designed to make the process as simple and comfortable as possible for users at home. The dose starts at 0.25 mg and is increased every 4 weeks to a usual maintenance dose of 2.4 mg (or 1.7 mg).

Known Benefits

Clinical trials have demonstrated that the Wegovy injection, combined with diet and exercise, can lead to significant weight loss. Because it's a weekly dose, some people find it convenient and easy to incorporate into their routine without the need to think about it every day.

Common Considerations

The primary consideration for many is the use of a needle. While the pen is designed for ease of use, the idea of self-injection can be a hurdle for some.

Like any medication, it has potential side effects. The most common are gastrointestinal issues, such as nausea, diarrhea, constipation, and vomiting, especially when starting the medication or increasing the dose. Proper storage is also a factor: pens are kept in the refrigerator, although the US label allows an unopened pen to be kept at up to 30°C (86°F) for up to 28 days if needed.

Wegovy Tablets: The Oral Alternative

For those who are needle-averse or simply prefer taking a pill, Wegovy tablets are an approved oral form of semaglutide for chronic weight management and for reducing cardiovascular risk in adults with heart disease and obesity or overweight. It contains the same active ingredient as the injection but is designed to be absorbed through the stomach.

How It's Used

The oral version is a daily tablet. The dose starts at 1.5 mg and steps up every 30 days (4 mg, then 9 mg) to the 25 mg maintenance dose. Its administration is very specific and crucial for it to be effective. The tablet must be taken in the morning on an empty stomach and swallowed whole.

You should take it with no more than four ounces (about 120 ml) of plain water. After swallowing the pill, you must wait at least 30 minutes before eating, drinking, or taking any other oral medications. This waiting period is essential to ensure the semaglutide is properly absorbed.

Potential Advantages

The most obvious advantage is the avoidance of needles. Taking a daily pill may feel less invasive and more routine for many people. The tablets are stored at room temperature in their original bottle, so there is no need to refrigerate pens.

Common Considerations

The main consideration is the strict daily routine. Forgetting to take the pill or not following the 30-minute rule can reduce the medication’s effectiveness. The need to plan your morning around taking your medication may be a significant lifestyle adjustment.

The side effect profile is similar to the injection, with gastrointestinal symptoms being the most commonly reported. Because it's a daily dose, it requires a consistent daily commitment.

A Side-by-Side Comparison

Let's break down the key differences to help you think about what might work best for your lifestyle.

Dosing Frequency

• Injection: Once a week. Set a day and it becomes a simple part of your weekly routine.
• Tablet: Once a day. Requires building a new daily habit.

Administration

• Injection: A quick, under-the-skin injection using a user-friendly pen.
• Tablet: A pill swallowed with a small amount of water, but with strict rules about taking it on an empty stomach and waiting 30 minutes before any other food, drink, or medication.

Efficacy

Both forms of semaglutide have been shown to be effective for weight management in clinical trials. In STEP 1, the 2.4 mg injection produced average weight loss of 14.9% at 68 weeks (vs 2.4% with placebo). In OASIS 4, the 25 mg tablet produced 13.6% at 64 weeks (vs 2.4% with placebo) when everyone was counted, and about 16.6% for people who stayed on treatment. These were separate trials, not a head-to-head comparison. The most suitable choice is less about which one is "stronger" and more about which one you can take most consistently and correctly.

Lifestyle Impact

• Injection: Requires comfort with self-injection and remembering to refrigerate the pens. The once-weekly schedule can be a "set it and forget it" advantage for busy individuals.
• Tablet: Avoids needles but demands a structured morning routine. This might be easy for some but challenging for others, especially those with variable schedules or who take other morning medications.

The Next Step: Talking to Your Doctor

Both forms share the same safety warnings, including a boxed warning about thyroid C-cell tumours (they should not be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2), and risks of pancreatitis, gallbladder problems, dehydration-related kidney problems, low blood sugar with insulin or a sulfonylurea, and serious allergic reactions. Seek urgent help for severe stomach pain that does not go away (it may spread to your back) or signs of a serious allergic reaction. Do not switch between forms on your own: the label sets specific rules for switching, so your prescriber needs to plan it.

Ultimately, choosing between the Wegovy injection and Wegovy tablets is a personal decision made in partnership with your healthcare provider. They can help you weigh the pros and cons based on your unique health profile, habits, and preferences.

Consider these questions to discuss with them:

• What is my comfort level with self-injection?
• How well can my lifestyle accommodate a strict 30-minute waiting period every morning?
• Am I more likely to remember a weekly task or a daily one?
• Do I have any other health conditions or take other medications that could influence this choice?

Your provider can offer a complete picture of the benefits and potential risks of each option, helping you make a confident and safe choice for your health journey. Consult your healthcare provider before starting any medication.

Sources

1. U.S. Food & Drug Administration. Wegovy (semaglutide) injection and tablets prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
3. Wharton, S., et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med, 393(11), 1077–1087. doi:10.1056/NEJMoa2500969
4. Knop, F. K., et al. (2023). Oral semaglutide 50 mg once daily in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01185-6/fulltext
5. European Medicines Agency. Wegovy (semaglutide) EPAR. https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
6. Mayo Clinic. Semaglutide (Subcutaneous Route). https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/side-effects/drg-20406730